Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers
Keywords: 
Alzheimer’s disease
sTREM2
Blood
Biomarkers
Neurofilament light chain
Issue Date: 
2019
Publisher: 
Springer Science and Business Media LLC
ISSN: 
1758-9193
Note: 
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Citation: 
Ashton, N.J. (Nicholas J.); Suárez-Calvet, M. (Marc); Heslegrave, A. (Amanda); et al. "Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers". Alzheimer's Research & Therapy. 11 (94), 2019, 2019
Abstract
Background: Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer’s disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ42 and Aβ40) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomarkers reflecting central nervous system pathophysiology and should be fully explored for biomarkers that show promise in CSF. Recently, soluble fragments of the triggering receptor expressed on myeloid cells 2 (sTREM2) protein in CSF have been reported to be increased in prodromal AD and also in individuals with TREM2 rare genetic variants that increase the likelihood of developing dementia. Methods: In this study, we measured the levels of plasma sTREM2 and plasma NFL using the MesoScale Discovery and single molecule array platforms, respectively, in 48 confirmed TREM2 rare variant carriers and 49 non-carriers. Results: Our results indicate that there are no changes in plasma sTREM2 and NFL concentrations between TREM2 rare variant carriers and non-carriers. Furthermore, plasma sTREM2 is not different between healthy controls, mild cognitive impairment (MCI) or AD. Conclusion: Concentrations of plasma sTREM2 do not mimic the recent changes found in CSF sTREM2.

Files in This Item:
Thumbnail
File
s13195-019-0545-5.pdf
Description
Size
686.69 kB
Format
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.